Lilly Extends ACCELERATE Phase 3 Trial for Cardiovascular Disease
The executive committee of the ACCELERATE study recommended Eli Lilly and Company Pharmaceutics extend their Phase 3 trial investigating the efficacy of evacetrapib for cardiovascular disease by 6 months. Eli Lilly accepted ... Read more